Standard Nivolumab Dosing
Nivolumab (Opdivo) uses fixed, flat doses for most approved indications, not weight-based adjustments. Adults typically receive 240 mg every 2 weeks or 480 mg every 4 weeks intravenously, regardless of body weight.[1][2]
When Is Weight Factoring In?
Weight influences dosing only in pediatric patients (12 years and older, weighing at least 40 kg). The regimen is 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks, capped at adult flat doses.[1] For adults, no adjustments occur based on body weight, BMI, or obesity.
Adjustments for Other Factors
Doses change based on toxicity (e.g., hold or discontinue for severe immune-related adverse events) or specific regimens like combination therapy with ipilimumab (1 mg/kg nivolumab + 3 mg/kg ipilimumab every 3 weeks).[2] Renal or hepatic impairment rarely requires changes, but severe cases need monitoring.[1]
Why Flat Dosing Over Weight-Based?
Flat doses simplify administration, reduce errors, and align with pharmacokinetic data showing consistent exposure across adult weights (40-130 kg). Studies confirm efficacy and safety without weight adjustments in adults.[3]
Patient Concerns on Dosing Variations
Overweight patients sometimes report variable responses, but guidelines do not recommend dose increases. Ongoing trials explore optimized flat dosing further.[2]
Sources
[1]: Nivolumab Prescribing Information (Bristol Myers Squibb)
[2]: [FDA Label for Opdivo](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[3]: Clinical Pharmacology Review - Nivolumab